newsfilter
← Latest News
PR Newswire·

Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach

ABBV
  • Allergan Aesthetics, an AbbVie company, launched AA Signature™ in the U.S. on Sept. 22, 2026, to provide patient-centric, multimodal consultation approaches.
  • The program's first protocol, AA Signature™: SKIN360, focuses on smoother, more hydrated skin using SKINVIVE by JUVÉDERM®, SkinMedica® HA 5® Hydra Collagen Hydrator, & BOTOX® Cosmetic.
  • AA Signature includes provider education & resources designed to support the 96% of patients interested in comprehensive aesthetic consultations.
  • Research cited indicates that practices using a comprehensive, multimodal approach see 68% higher patient retention than those treating single concerns.
  • A study found that eight out of ten patients proceed with treatment after a comprehensive assessment & aligning on a plan involving two or more in-office products or procedures.
  • The SKIN360 assessment allows specialists to explore treatments for the face, neck, & décolleté to achieve individualized aesthetic goals.
  • Subsequent consultation protocols addressing lift, structure, skin firmness, & facial definition are scheduled to debut through 2027.
  • The safety & efficacy of combining the three products in the SKIN360 assessment have not been studied.
  • BOTOX® Cosmetic is approved for temporary improvement of moderate to severe forehead lines, crow's feet, frown lines, & platysma bands, with warnings regarding serious side effects like swallowing difficulties & toxin spread.
  • SKINVIVE by JUVÉDERM® is approved for improving cheek skin smoothness & reducing neck lines in adults over 21, with risks including vascular injection complications & vision abnormalities.
  • SkinMedica® products are classified as cosmetics & are not FDA-approved drug products.
  • Providers can access additional training materials & resources through Allergan Aesthetics business development representatives.